Northern Trust
VINC

Northern Trust’s Vincerx Pharma, Inc. Common Stock VINC Stock Holding History

Northern Trust’s Portfolio VINC Stock Details VINC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,715
Closed -$9.01K – 4547
2024
Q4 		$9.01K Hold
1,715
– – ﹤0.01% 4427
2024
Q3 		$24.6K Hold
1,715
– – ﹤0.01% 4318
2024
Q2 		$27.8K Sell
1,715
-1
-0.1% -$25 ﹤0.01% 4295
2024
Q1 		$174K Buy
1,716
+435
+34% +$27.5K ﹤0.01% 3942
2023
Q4 		$30.2K Hold
1,281
– – ﹤0.01% 4319
2023
Q3 		$25.9K Hold
1,281
– – ﹤0.01% 4284
2023
Q2 		$33.3K Hold
1,281
– – ﹤0.01% 4308
2023
Q1 		$26.6K Hold
1,281
– – ﹤0.01% 4398
2022
Q4 		$26.1K Sell
1,281
-2
-0.2% -$38 ﹤0.01% 4431
2022
Q3 		$35K Hold
1,283
– – ﹤0.01% 4423
2022
Q2 		$34K Sell
1,283
-5,710
-82% -$254K ﹤0.01% 4528
2022
Q1 		$560K Sell
6,993
-184
-3% -$22.7K ﹤0.01% 3697
2021
Q4 		$1.46M Buy
7,177
+1,159
+19% +$289K ﹤0.01% 3385
2021
Q3 		$1.95M Buy
6,018
+2,811
+88% +$820K ﹤0.01% 3304
2021
Q2 		$834K Buy
3,207
+2,308
+257% +$703K ﹤0.01% 3572
2021
Q1 		$347K Buy
+899
New +$363K ﹤0.01% 3931

Other funds holding VINC

SRC
Sage Rhino Capital Menlo Park, California $535M AUM 24.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Northern Trust's VINC Position: Q1 2025 in Review

Northern Trust sold out of Vincerx Pharma, Inc. Common Stock (VINC) in Q1 2025, closing a stake of 1,715 shares — an estimated $9.01K sold.

Northern Trust first reported a position in VINC in Q1 2021 and held it in 16 quarters. The position peaked at $1.95M in Q3 2021. 14 funds tracked by Wall St. Rank hold VINC as of Q1 2025.

  • Northern Trust reported no remaining Vincerx Pharma, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Northern Trust sold 1,715 Vincerx Pharma, Inc. Common Stock shares in Q1 2025, an estimated $9.01K.
  • Northern Trust first reported a position in Vincerx Pharma, Inc. Common Stock in Q1 2021 and held it in 16 quarters.
  • Northern Trust's Vincerx Pharma, Inc. Common Stock position peaked at $1.95M in Q3 2021.
  • 14 funds tracked by Wall St. Rank held Vincerx Pharma, Inc. Common Stock as of Q1 2025.

Based on Northern Trust's 13F filing for Q1 2025, filed 13 May 2025.